In April, Antigenics announced that the Russian Ministry of Public Health issued a registration certificate for the use of Oncophage (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008.

View press release

“The global vaccine business is surging. ... New vaccines are creating new markets. ... Therapeutic vaccines remain a potential high-growth area.” 
       Merrill Lynch Vaccine Report, August 7, 2006

“… vaccines represent a major source of new growth. ... The vaccine market is expected to more than double between 2004  [$8B] to 2009 [$18B].”  
       Mercer Management Consulting Vaccine Report, 2006

“The vaccine market (US$10B in 2005) is expected to grow by 13% p.a. to 2010, twice as fast as Pharma.” 
       Exane BNP Paribas Vaccine Report, July 10, 2006

“After years of neglect, big pharma has rediscovered vaccines as a growth opportunity, attracted by an oligopolistic market structure and the absence of direct generic risk.” 
        Bear Stearns Vaccine Report, May 16, 2006

Antigenics Earnings Call (07/31/08)

Antigenics Receives NASDAQ Delisting Notice (12/23/2008)

Antigenics Receives NASDAQ Delisting Notification (11/26/2008)

Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage® Cancer Vaccine in Glioma Presented at the Society for Neuro-Oncology’s Annual Meeting (11/24/2008)

Antigenics Reports Third Quarter 2008 Financial Results (11/5/2008)

Antigenics to Present at the Rodman and Renshaw 10th Annual Healthcare Conference (11/3/2008)

BioWorld Today
“As CEO Sweetens the Pot, Antigenics Raises $26.1M” (01/10/08)

All events »